[Revisiting the vasopressin V2 receptor]
Meng Li1,2, Wei-Dong Wang2, Chun-Ling Li1
1Department of Physiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
Sheng Li Xue Bao : [Acta Physiologica Sinica]
|January 9, 2025
Summary
Arginine vasopressin (AVP) V2 receptor (V2R) research has advanced, revealing its roles beyond water reabsorption. New insights into V2R
Area of Science:
- Endocrinology and Physiology
- Molecular Biology
- Pharmacology
Background:
- Arginine vasopressin (AVP) regulates vital physiological functions via V1a, V1b, and V2 receptors.
- The vasopressin V2 receptor (V2R) is primarily known for its role in renal water reabsorption.
- Recent technological advancements have expanded the understanding of V2R's distribution and function.
Purpose of the Study:
- To provide a concise overview of recent research on the vasopressin V2 receptor (V2R).
- To summarize current knowledge on V2R's physiological and pathophysiological roles.
- To highlight recent developments in V2R-targeted drug discovery.
Main Methods:
- Review of recent scientific literature utilizing advanced imaging and bioinformatics.
- Analysis of studies involving V2R overexpression, activation, and antagonism.
- Synthesis of findings on V2R's tissue distribution, protein binding, and disease relevance.
Main Results:
- Enhanced understanding of V2R's complex microstructure and protein interactions.
- Identification of V2R's involvement in various diseases beyond renal function.
- Emerging therapeutic strategies targeting V2R for different medical conditions.
Conclusions:
- V2R is a multifaceted receptor with significant implications in physiology and pathology.
- Continued research into V2R is crucial for developing novel therapeutic interventions.
- The V2R field is rapidly evolving, offering new avenues for drug development.
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
579
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
579
Adrenergic Receptors: ɑ Subtype
1.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Antihypertensive Drugs: Vasodilators
473
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
473
ATP Driven Pumps III: V-type Pumps
3.6K
V-type pumps are ATP-driven pumps found in the vacuolar membranes of plants, yeast, endosomal and lysosomal membranes of animal cells, plasma membranes of a few specialized eukaryotic cells, and some prokaryotes. They are also known as the V1Vo-ATPase, that couple ATP hydrolysis to transport protons against a concentration gradient.
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
3.6K
Adrenergic Receptors: β Subtype
1.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.5K


